Remove Medicine Remove Pharma Production Remove Regulation Remove Sales
article thumbnail

Russia’s focus on domestic pharma production could shield it from sanctions’ effects

Pharmaceutical Technology

Compared with other emerging pharmaceutical markets (such as India and China, covered in previous Emerging Market Outsourcing Reports), Russian facilities lack many US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals, meaning Russian manufacturing is more focused on the domestic market.

article thumbnail

COVID-19 and the digital pharma marketing revolution

pharmaphorum

Until 2020, pharma had lagged other industries in its investment in digital marketing. In the US, TV advertising for pharma products is still a big business, but this is mainly aimed at patients. A report from eMarketer came to an identical conclusion, estimating that US pharma would spend $9.53 This is an increase in 14.2%

article thumbnail

Brazil: untapped market for big pharma manufacturing

Pharmaceutical Technology

Brazilian pharma production sites are involved in Covid-19 vaccine and therapy manufacture. There are a total of 43 manufacturing sites, most of which have approval from the Brazilian regulator ANVISA, but only 13 sites have FDA and/or EMA approval, showing an emphasis on domestic and regional production.